转移性前列腺癌铂类敏感性:组织学是否重要?
该回顾性研究纳入2005年以来在杜克大学接受铂类治疗的73例转移性去势抵抗性前列腺癌(mCRPC)患者,比较神经内分泌前列腺癌(NEPC)与腺癌的组织学对铂类敏感性的预测价值。一线治疗中NEPC患者部分缓解率63%高于腺癌29%(p=0.017),中位rPFS分别为5.1个月和4.3个月,中位OS分别为8.5个月和10.0个月。研究提示NEPC组织学富集铂类敏感人群,但20-30%腺癌患者仍可从铂类化疗中临床获益。
要点
- 一线铂类治疗NEPC部分缓解率63% vs 腺癌29%(p=0.017)。
- NEPC中位rPFS 5.1个月 vs 腺癌4.3个月,中位OS 8.5 vs 10.0个月。
- 腺癌中20-30%患者对铂类有临床获益,建议评估DNA修复酶突变。
核心结论
- NEPC组织学富集铂类敏感性,但20-30%腺癌患者仍可从铂类化疗中临床获益。
- 建议评估DNA修复酶胚系或体细胞突变作为铂类反应性的分子预测因素。
研究设计与样本
- 回顾性研究,纳入2005年以来杜克大学73例接受铂类(顺铂、卡波铂或奥沙利铂)治疗的mCRPC患者。
- 收集临床特征、组织学、影像、安全性和神经内分泌转化数据,影像按RECIST v1.1重新评估反应和rPFS。
主要发现
- 数据库检索确定73例接受铂类治疗的mCRPC患者,其中3例原发NEPC和小细胞前列腺癌,14例NEPC转化。
- 一线治疗中NEPC患者10例(63%)达部分缓解(PR),腺癌患者14例(29%)达PR(p=0.017)。
- NEPC中位rPFS为5.1个月(3.1-7.8),腺癌为4.3个月(3.0-5.2)。
- NEPC中位OS为8.5个月(6.4-20.1),腺癌为10.0个月(8.0-14.4)。
- 接受铂类化疗的NEPC患者(n=14)PSA较基线下降>30%、>50%、>90%的比例分别为64%、57%、29%;腺癌患者(n=50)分别为48%、30%、14%。
临床怎么用
- NEPC组织学可富集铂类敏感人群,但腺癌患者中亦有20-30%可从铂类化疗中临床获益。
- 分子预测因素如DNA修复酶胚系或体细胞突变应被评估用于铂类反应性预测。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platinum-based chemotherapy is effective in men with neuroendocrine prostate cancer (NEPC), but it is unclear whether histology (adenocarcinoma vs. non-adenocarcinoma NEPC variants) is predictive of platinum sensitivity. Given that NEPC exists as a spectrum, there may be men with adenocarcinoma who might benefit from platinum chemotherapy, particularly those men with DNA repair defects. METHODS: This was a retrospective study of all of the men seen at Duke University since 2005 who had metastatic castration-resistant prostate cancer (mCRPC) and were treated with a platinum agent. Data surrounding clinical features, histology, imaging, safety, and neuroendocrine transformation were collected. Scans were re-reviewed using RECIST v1.1 criteria to estimate responses as well as calculate radiographic progression-free survival (rPFS). RESULTS: A database search identified 73 men with mCRPC treated with cisplatin, carboplatin, or oxaliplatin. There were three men with primary NEPC and small cell prostate cancer, and 14 with a NEPC transformation. In the first-line setting, 10 (63%) men with NEPC had a partial response (PR) compared with 14 (29%) of the men with adenocarcinoma (p = 0.017), with a median rPFS of 5.1 mo (3.1-7.8) and 4.3 mo (3.0-5.2 mo), respectively. The median overall survival was 8.5 mo (6.4-20.1 mo) for men with NEPC compared to 10.0 mo (8.0-14.4) in men with adenocarcinoma. Prostate-specific antigen (PSA) declines meeting >30%, >50%, and >90% criteria from baseline were observed in 64/57/29% of NEPC patients (n = 14) treated with platinum chemotherapy vs. 48/30/14% of men with prostate adenocarcinoma (n = 50), respectively. CONCLUSIONS: This study suggests that NEPC histology enriches for platinum sensitivity, but that an important minority group (20-30%) of men with adenocarcinoma have a clinical benefit with platinum-based chemotherapy. Molecular predictors, such as germline or somatic mutations in DNA repair enzymes, should be evaluated for platinum responsiveness.
引用
- Humeniuk MS, Gupta RT, Healy P, et al. Platinum sensitivity in metastatic prostate cancer: does histology matter? Prostate Cancer Prostatic Dis. 2017. PMID: 29230006. doi:10.1038/s41391-017-0017-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。